184 related articles for article (PubMed ID: 3488024)
1. [Effective mechanisms of BRM, with special reference to induction of autologous tumor cell-killing (ATK) activity by OK-432].
Hoshino T; Uchida A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1277-84. PubMed ID: 3488024
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytes by the streptococcal preparation OK432.
Uchida A
Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):81-4. PubMed ID: 2423823
[TBL] [Abstract][Full Text] [Related]
3. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils.
Hayashi Y; Torisu M
Surgery; 1990 Jan; 107(1):74-84. PubMed ID: 2404351
[TBL] [Abstract][Full Text] [Related]
4. In vitro potentiation of human natural killer cell activity by a streptococcal preparation, OK-432: interferon and interleukin-2 participation in the stimulation with OK-432.
Wakasugi H; Kasahara T; Minato N; Hamuro J; Miyata M; Morioka Y
J Natl Cancer Inst; 1982 Oct; 69(4):807-12. PubMed ID: 6181282
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of a Streptococcus pyogenes preparation (OK-432). II. Analysis of the cytotoxic lymphocytes induced by OK-432 injection into tumor-bearing F344 rats.
Fukui H; Reynolds CW
J Natl Cancer Inst; 1987 Nov; 79(5):1019-24. PubMed ID: 3500354
[TBL] [Abstract][Full Text] [Related]
6. [The management of malignant ascites with a streptococcal preparation, OK-432: relation between the clinical effect and auto-tumor cell killing activity by OK-432-induced ascites-derived lymphocytes].
Katano M; Yamamoto H; Mizoguchi T; Hidaka K; Hisatsugu T; Torisu M
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2464-8. PubMed ID: 3497612
[TBL] [Abstract][Full Text] [Related]
7. Generation of activated killer-like cells by OK-432-mediated production of interleukin 1, interleukin 2, and interferon-gamma in vitro.
Ujiie T
Jpn J Exp Med; 1987 Dec; 57(6):333-8. PubMed ID: 3131563
[TBL] [Abstract][Full Text] [Related]
8. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432.
Uchida A; Micksche M
J Natl Cancer Inst; 1983 Oct; 71(4):673-80. PubMed ID: 6413742
[TBL] [Abstract][Full Text] [Related]
9. Lysis of fresh human tumor cells by autologous large granular lymphocytes and T-lymphocytes: two distinct killing activities induced by coculture with autologous tumor.
Uchida A; Moore M
J Natl Cancer Inst; 1984 Dec; 73(6):1285-92. PubMed ID: 6239944
[TBL] [Abstract][Full Text] [Related]
10. Role of NK cell cytotoxic factor against fresh human tumors.
Uchida A; Fukata H
Nat Immun; 1993; 12(4-5):267-78. PubMed ID: 8257831
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of NK activation by OK-432 (Streptococcus pyogenes). I. Spontaneous release of NKCF and augmentation of NKCF production following stimulation with NK target cells.
Bonavida B; Katz J; Hoshino T
Cell Immunol; 1986 Oct; 102(1):126-35. PubMed ID: 3492275
[TBL] [Abstract][Full Text] [Related]
12. Natural killer (NK) cell activating factor released from murine thymocytes stimulated with an anti-tumor streptococcal preparation, OK-432.
Shitara K; Ichimura O; Mitsuno T; Osawa T
J Immunol; 1985 Feb; 134(2):1039-47. PubMed ID: 2578148
[TBL] [Abstract][Full Text] [Related]
13. OK-432-mediated augmentation of antitumor immunity and generation of cytotoxic T lymphocytes.
Ujiie T
Jpn J Exp Med; 1987 Apr; 57(2):103-15. PubMed ID: 3499533
[TBL] [Abstract][Full Text] [Related]
14. [Oral administration of OK-432 (picibanil). (8th report) clinical application: its immunomodulatory effects on the patients with gastrointestinal cancers].
Nio Y; Ohgaki K; Tsuchitani T; Imai S; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Tobe T
Nihon Gan Chiryo Gakkai Shi; 1989 Aug; 24(8):1607-15. PubMed ID: 2809385
[TBL] [Abstract][Full Text] [Related]
15. Augmentation by OK-432 of generation of culture-induced killer cells.
Ujiie T
Jpn J Exp Med; 1987 Jun; 57(3):153-61. PubMed ID: 3682231
[TBL] [Abstract][Full Text] [Related]
16. Effect of OK-432 on cytotoxic activity in cancer patients without tumor burden.
Fujieda S; Saito H; Isobe Y; Nakagawara G; Nishi O; Nagahara K; Watanabe Y; Hoshino T
Anticancer Res; 1992; 12(6B):1941-5. PubMed ID: 1341892
[TBL] [Abstract][Full Text] [Related]
17. [Anticancer effects of OK-432 (2). Anticancer actions of M phi activated by OK-432].
Saito M; Aonuma E; Noda T; Nakadate I; Nanjo M; Ebina T; Ishida N
Gan To Kagaku Ryoho; 1983 May; 10(5):1363-71. PubMed ID: 6870302
[TBL] [Abstract][Full Text] [Related]
18. [The effect of OK-432 in the treatment of primary lung cancer].
Kishimoto T; Okada K
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430
[TBL] [Abstract][Full Text] [Related]
19. Enhanced generation of OK-432-induced killer cells by interleukin 2.
Ujiie T
Jpn J Exp Med; 1987 Jun; 57(3):183-8. PubMed ID: 3500332
[TBL] [Abstract][Full Text] [Related]
20. Modulation of NK activity in regional lymph nodes by preoperative immunotherapy with OK-432 in patients with cancer of the oral cavity.
Vinzenz K; Matejka M; Watzek G; Porteder H; Neuhold N; Micksche M
Cancer Detect Prev Suppl; 1987; 1():463-75. PubMed ID: 3480060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
